These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 27296819

  • 21. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
    Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG.
    Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336
    [Abstract] [Full Text] [Related]

  • 22. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
    Singh D, Magnussen H, Kirsten A, Mindt S, Caracta C, Seoane B, Jarreta D, Garcia Gil E.
    Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
    [Abstract] [Full Text] [Related]

  • 23. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S.
    Respir Res; 2017 Jan 06; 18(1):8. PubMed ID: 28061907
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
    Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A.
    Eur Respir J; 2016 Oct 06; 48(4):1030-1039. PubMed ID: 27492833
    [Abstract] [Full Text] [Related]

  • 25. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
    Haley R, Gupta N, Sethi S.
    Expert Rev Clin Pharmacol; 2020 Feb 06; 13(2):103-113. PubMed ID: 31951778
    [Abstract] [Full Text] [Related]

  • 26. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J.
    Lancet; 2016 Sep 03; 388(10048):963-73. PubMed ID: 27598678
    [Abstract] [Full Text] [Related]

  • 27. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS, Morjaria JB.
    Ther Adv Respir Dis; 2015 Apr 03; 9(2):56-68. PubMed ID: 25754881
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E.
    Chest; 2012 Mar 03; 141(3):745-752. PubMed ID: 21903737
    [Abstract] [Full Text] [Related]

  • 29. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C.
    Respir Res; 2020 May 25; 21(1):128. PubMed ID: 32450869
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
    Lee SH, Lee J, Yoo KH, Uh ST, Park MJ, Lee SY, Kim JY, Kim DK, Kim SJ, Lee KH, Yoo CG.
    Respirology; 2015 Nov 25; 20(8):1222-8. PubMed ID: 26370136
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
    Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, Donohue JF, Bateman ED, Gross NJ, Lamarca R, Caracta C, Gil EG.
    Respir Res; 2011 Apr 26; 12(1):55. PubMed ID: 21518460
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, Sethi S, Spangenthal S, Gottschlich GM, Rodriguez-Roisin R, Arora S, Siler TM, Siddiqui S, Darken P, Fischer T, Maes A, Golden M, Orevillo C, Reisner C.
    Chest; 2017 Feb 26; 151(2):340-357. PubMed ID: 27916620
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators.
    COPD; 2012 Apr 26; 9(2):90-101. PubMed ID: 22320148
    [Abstract] [Full Text] [Related]

  • 34. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
    Rennard SI, Scanlon PD, Ferguson GT, Rekeda L, Maurer BT, Garcia Gil E, Caracta CF.
    Clin Drug Investig; 2013 Dec 26; 33(12):893-904. PubMed ID: 24085591
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C, Pearle J, Kerwin EM, Rose ES, Darken P.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 26; 13():1965-1977. PubMed ID: 29950826
    [Abstract] [Full Text] [Related]

  • 36. Aclidinium bromide for stable chronic obstructive pulmonary disease.
    Ni H, Soe Z, Moe S.
    Cochrane Database Syst Rev; 2014 Sep 19; 2014(9):CD010509. PubMed ID: 25234126
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.
    Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Chuecos F, Garcia Gil E, Chapman KR.
    Adv Ther; 2021 Oct 19; 38(10):5381-5397. PubMed ID: 34528220
    [Abstract] [Full Text] [Related]

  • 38. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C.
    Lancet Respir Med; 2018 Oct 19; 6(10):747-758. PubMed ID: 30232048
    [Abstract] [Full Text] [Related]

  • 39. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT, Tashkin DP, Skärby T, Jorup C, Sandin K, Greenwood M, Pemberton K, Trudo F.
    Respir Med; 2017 Nov 19; 132():31-41. PubMed ID: 29229103
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
    Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, Gil EG.
    COPD; 2013 Aug 19; 10(4):511-22. PubMed ID: 23819698
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.